HC Wainwright Forecasts Weaker Earnings for Journey Medical

Journey Medical Corporation (NASDAQ:DERM) – Stock analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Journey Medical in a report released on Thursday, August 13th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.06) per share for the year, down from their prior forecast of ($0.05). The consensus estimate for Journey Medical’s current full-year earnings is ($0.02) per share.

A number of other equities research analysts have also weighed in on DERM. B. Riley Financial reaffirmed a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Journey Medical in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Friday, July 17th. Finally, Wall Street Zen raised Journey Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.00.

Journey Medical Stock Down 3.9%

DERM stock opened at $6.46 on Monday. Journey Medical has a one year low of $4.31 and a one year high of $9.56. The stock has a market capitalization of $177.88 million, a PE ratio of -29.36 and a beta of 1.08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59. The company has a fifty day moving average of $6.62 and a 200-day moving average of $6.58.

Journey Medical (NASDAQ:DERM) last released its earnings results on Wednesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The business had revenue of $18.51 million for the quarter, compared to analyst estimates of $18.36 million. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.

Institutional Trading of Journey Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after acquiring an additional 4,048 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Journey Medical in the 2nd quarter valued at about $36,000. Royal Bank of Canada lifted its holdings in Journey Medical by 42.7% in the 1st quarter. Royal Bank of Canada now owns 8,175 shares of the company’s stock valued at $38,000 after purchasing an additional 2,446 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in Journey Medical in the 2nd quarter valued at about $41,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Journey Medical during the 1st quarter worth about $48,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.